Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHMB monotherapy versus PHMB + propamidine for Acanthamoeba keratitis
2016-001823-30Phase 3Unknown
- Sponsor
- SIFI SpA
- Start
- Feb 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Acanthamoeba keratitis (AK) comparing PHMB monotherapy with PHMB + propamidine combination therapy (2 arms). Primary endpoint: Clinical Resolution Rate at 12 months. Status: unknown.
02
Drugs
polihexanidepropamidine isetionate
03
Conditions
Acanthamoeba keratitis (AK)
Beyond the preview
Go deeper on 2016-001823-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001823-30.